Figure 1. Components of the c-Jun pathway are regulated during development, Wallerian degeneration, and in vitro differentiation. A–D show Western blots. (A) Down-regulation of phospho–c-Jun and c-Jun proteins in sciatic nerve from embryonic day (E) 18 to adult. (B) Rapid up-regulation of JNK–c-Jun pathway components at 20 min (20′)–12 h after nerve cut when compared with contralateral control (Con). (C) Strong increase in phospho–c-Jun at 1, 2, and 3 d after transection (Cut) compared with the contralateral control (Con). (D) Activation of cAMP-related pathways (1 mM db-cAMP for 24 h) decreases c-Jun and phospho–c-Jun and increases the myelin proteins Krox-20 and periaxin, whereas phospho-ERK1/2 levels are unchanged. (E–H) Double immunolabeling of controls (E and F) and cells treated with 1 mM db-cAMP for 3 d (G and H), with phospho–c-Jun and P0 antibodies. Note that cAMP induces P0 and suppresses phospho–c-Jun levels in the P0-positive cells. Bar, 15 μm.
Figure 1.

Components of the c-Jun pathway are regulated during development, Wallerian degeneration, and in vitro differentiation. A–D show Western blots. (A) Down-regulation of phospho–c-Jun and c-Jun proteins in sciatic nerve from embryonic day (E) 18 to adult. (B) Rapid up-regulation of JNK–c-Jun pathway components at 20 min (20′)–12 h after nerve cut when compared with contralateral control (Con). (C) Strong increase in phospho–c-Jun at 1, 2, and 3 d after transection (Cut) compared with the contralateral control (Con). (D) Activation of cAMP-related pathways (1 mM db-cAMP for 24 h) decreases c-Jun and phospho–c-Jun and increases the myelin proteins Krox-20 and periaxin, whereas phospho-ERK1/2 levels are unchanged. (E–H) Double immunolabeling of controls (E and F) and cells treated with 1 mM db-cAMP for 3 d (G and H), with phospho–c-Jun and P0 antibodies. Note that cAMP induces P0 and suppresses phospho–c-Jun levels in the P0-positive cells. Bar, 15 μm.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal